Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Nieuwe hoogleraar wil immuuntherapie voor melanomen personaliseren
nov 2020 | Dermato-oncologie, Immuuntherapie